linjc16/ctgov huggingface dataset:
Observational Study of Survival Outcomes of Stage IV Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Patients diagnosed with Stage IV cancer (solid tumors only) are evaluated to determine whether they are candidates for traditional chemotherapy. If eligible, patients are offered traditional chemotherapy, low-dose chemotherapy, or palliative care. If ineligible, patients are offered low-dose chemotherapy or palliative care. Patients will be monitored for 5 years and survival data recorded.

Official Title
-----------------
Observational Study of Survival Times of Stage IV Cancer Patients

Conditions
-----------------
Stage IV Cancer (Solid Tumors Only), Survival

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presenting with Stage IV cancer (solid tumors only) Exclusion Criteria: Patient declines inclusion
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1. Eligible RCT/Elect RCT<br>Eligible for regular chemotherapy, elects and receives regular chemotherapy | |
| 2. Eligible RCT/Elect LDC<br>Eligible for regular chemotherapy, elects and receives low-dose chemotherapy | |
| 3. Eligible RCT/Elect PCO<br>Eligible for regular chemotherapy, elects and receives palliative care only | |
| 4. Ineligible RCT/Elect LDC<br>Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy | |
| 5. Ineligible RCT/Elect PCO<br>Ineligible for regular chemotherapy, elects and receives palliative care only | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival |  | months 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stage IV cancer, Survival
Handheld Computers to Improve Adherence to Anti-HIV Drug Regimens

Study Overview
=================
Brief Summary
-----------------
While anti-HIV drugs can significantly reduce viral loads, the medication regimens can be complex, and patients must take them correctly for the best effect. Nonadherent patients risk developing drug resistant HIV strains. The purpose of this study is to evaluate the effectiveness of a handheld computerized system designed to help patients take their drugs correctly.

Detailed Description
-----------------
As the use of protease inhibitors and other antiretroviral medications has increased, multiple drug resistant HIV strains have emerged, demonstrating the need for improved patient adherence to complex drug regimens. Individual computerized adherence systems have been proposed as a mechanism for improving patient adherence. This study will utilize advanced computer and communication technologies to produce a handheld (PDA) product for HIV/AIDS patients. The system serves as a patient reminder system, addresses problems of missed medications, and monitors severity of side effects. This study will evaluate the efficacy of the system as an adherence intervention. Participants in the study will be randomized to either the intervention or a control group. Participants will use the PDA daily for medication reminders, alarms, adherence tracking, and as a source of information on HIV/AIDS. The study will last 15 weeks. Each participant will have 6 study interviews and 2 quality control interviews. Study interviews will include adherence questionnaires, blood tests for viral load and CD4 data, and quality of life assessments.

Official Title
-----------------
Compliance Enhancement In HIV/AIDS Patients

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Device: Medication Reminder System/Adherence Tracker


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria HIV positive Currently taking medications for HIV/AIDS.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Medication Reminder System/Adherence Tracker|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adherence, Treatment Experienced
Optical Coherence Tomography-based Positioning for Macular Hole Surgery

Study Overview
=================
Brief Summary
-----------------
The efficacy of macular hole (MH) surgery with the halting of prone positioning by monitoring the MH closure in the swept source optical coherence tomographic (SS-OCT) images was compared with the surgery by the surgeon's decision. The macular hole closure and visual outcome were compared.

Detailed Description
-----------------
The efficacy of macular hole (MH) surgery with the halting of prone positioning by monitoring the MH closure in the swept source optical coherence tomographic (SS-OCT) images was compared with the surgery by the surgeon's decision. All eyes were treated by pars plana vitrectomy, internal limiting membrane peeling, and gas tamponade. MH closure was defined as a connection of the edges of the sensory retina in the SS-OCT images.The macular hole closure and visual outcome were compared.

Official Title
-----------------
Duration of Prone Positioning After Macular Hole Surgery Determined by Swept Source Optical Coherence Tomography

Conditions
-----------------
Macular Hole Surgery

Intervention / Treatment
-----------------
* Procedure: Macular hole surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients were followed more than 2 months. Exclusion Criteria: Eye with axial length more than 26.0 mm

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SS-OCTdetermined group<br>Eyes with macular hole surgery that the postoperative prone positioning was discontinued after detecting a closure by SS-OCT | Procedure: Macular hole surgery<br>* Vitrectomy with internal limiting membrane removal and gas tamponade<br>* Other names: Vitrectomy;|
| Control group<br>Eyes with macular hole surgery that the halting of the prone position was determined by the surgeon | Procedure: Macular hole surgery<br>* Vitrectomy with internal limiting membrane removal and gas tamponade<br>* Other names: Vitrectomy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Macular hole closure | Closure of macular hole | Changes from baseline to 1, 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity before and after surgery | Vision | Changes from baseline to 1, 2 months |
Improvement of Periprocedural Guidewire Management for Cardiac Catheterization (PTCA)

Study Overview
=================
Brief Summary
-----------------
Periprocedural management of guidewire placement and removal in patients needing cardiac catheterization by use of marking of the access site and removal procedure due to a graduated scheme

Detailed Description
-----------------
Before elective cardiac catheterization, patients undergo an ultrasound-guided marking of the bifurcation of the common femoral artery in order to access the vascular complication rate compared tho those of non-marked patients. Concerning the removal of the guided wire, patients will be treated due to a graduated scheme taking care of different risk levels. This procedure should improve clinical routine, but the efficacy and safety have to be assessed. Depending on the risk level, the guide wire will be removed either by an ambulance officer or emergency medical technician, assistant personal of the cardiac catheterization operating room or by a physician specialist in intensive care. Both methods should lead to quality assurance.

Official Title
-----------------
Improvement of Periprocedural Guidewire Management for Cardiac Catheterization (PTCA)Using Preprocedural Marking of the Arterial Access Site and a Graduated Scheme for Removal of the Guidewire

Conditions
-----------------
Cardiac Catheterization

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective cardiac catheterization or PCI or emergency interventions Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients for elective catheterization without special risks | |
| 2<br>patients for elective catheterization with special risks | |
| 3<br>patients for PCI without GP IIb/IIIa | |
| 4<br>Patients for PCI with GPIIb/IIIa and emergencies | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease of vascular complications by marking of the access site |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of guide wire removal procedure by using the graduated scheme |  | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
guide wire, cardiac catheterization, ultrasound-guided examination of the access site, graduated scheme, elective and non elective cardiac catheterization
Prevalence of Obstructive Sleep Apnea (OSA) and the Association With Cognitive Impairment

Study Overview
=================
Brief Summary
-----------------
The study is aimed to carry out an epidemiology study investigating the prevalence of obstructive sleep apnea (OSA) and the association with cognitive impairment.

Official Title
-----------------
Prevalence of Obstructive Sleep Apnea (OSA) and the Association With Cognitive Impairment

Conditions
-----------------
Obstructive Sleep Apnea, Cognitive Impairment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have stability of at least 4 weeks on permitted medications (i.e. medications known not to affect sleep architecture or circadian rhythms). Exclusion Criteria: Suspected dementia or a score of <24 on the mini-mental state examination A diagnosis of neurological disorders (e.g. Parkinson's Disease, Epilepsy, Multiple Sclerosis) Psychiatric disorders including current major depression; bipolar disorder; schizophrenia Other known clinically significant sleep disorders (e.g. narcolepsy) Been currently receiving CPAP or bi-level pressure for OSA

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects having apnea-hypopnea index of more than 5 |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of cerebrovascular disease |  | 5 years | 
| Montreal Cognitive Assessment |  | 5 years |
Management of Diabetes Mellitus Patients With Retinopathy

Study Overview
=================
Brief Summary
-----------------
Aim of this NIS is to retrospectively document the management of diabetic patients with retinopathy in a naturalistic setting in Switzerland. Following elements are going to be analyzed: which medication are used to keep blood pressure under control? which medication are used for metabolic control? the average control level of metabolism and blood pressure is compliant with the international guidelines? laser photocoagulation plays a role in the control of metabolism and blood pressure? there are differences in the control of metabolism and blood pressure between patients with DM I or DM II? there is an influence of renal failure on the choose of medication?

Official Title
-----------------
Management of Diabetes Mellitus Patients With Retinopathy

Conditions
-----------------
Retinopathy, Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetic patients Diabetic retinopathy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Diabetic patients with retinopathy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood lipids, glycemia, HbA1C, blood creatinine, proteinuria, body weight |  | every 3 months | 
| evolution of diabetic retinopathy |  | every 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| concomitant medication |  | every 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes Mellitus, retinopathy, Management of diabetic patients with retinopathy
Optimizing DBS Electrode Placement and Programming

Study Overview
=================
Brief Summary
-----------------
Deep brain stimulation (DBS) has become the primary surgical therapy for the treatment of motor symptoms associated with Parkinson's disease (PD), and for essential tremor (ET). Although an effective and relatively safe procedure with expanding indications, opportunities exist for the optimization of the current procedure. The investigators therefore propose, in a group of patients undergoing DBS surgery for the treatment of PD or ET, to use a combination of high-field imaging modalities, intraoperative electrophysiology, external sensor interfaces, and computational modeling, to gather information on the utility of using these techniques to optimize DBS electrode placement and programming.

Official Title
-----------------
Optimizing DBS Electrode Placement and Programming Using a Combination of High-Field MRI, Intraoperative Electrophysiology, and Computational Modeling.

Conditions
-----------------
Parkinson's Disease, Essential Tremor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A diagnosis of idiopathic Parkinson's disease or essential tremor Ability to provide informed consent Exclusion Criteria: Claustrophobia or other conditions that prevent undergoing MR imaging MMSE score < 23 Significant neurological diagnosis other than PD or ET. Idiopathic dystonia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distance between Electrophysiology Results and Modeling Predictions (mm) | A comparison between electrophysiology results and modeling predictions will be made post-operatively. | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Deep Brain Stimulation (DBS), Parkinson's Disease, Essential Tremor
Moletest Clinical Study in Scotland

Study Overview
=================
Brief Summary
-----------------
To evaluate an iPad based photoimage analysis system (Moletest) for improving discrimination of benign from malignant suspicious skin lesions or moles. Specifically the objective is to demonstrate that the Moletest system is able with a sufficient degree of confidence (95%) to identify lesions which are benign

Official Title
-----------------
A Clinical Study to Evaluate the Ability of an iPad Based Photographic Image Analysis System to Discriminate Benign Skin Lesions From Those Considered Suspect for Melanoma

Conditions
-----------------
Melanoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients referred to the Dermatology Department, Lanarkshire Hospitals during a period to be defined for assessment of suspicious skin lesions (cutaneous moles) will be eligible for inclusion in the study. There are no age limits but patients under the age of 18 years will also have their inclusion subject to parental/guardian consent Exclusion Criteria: There is no exclsion criteria
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical accuracy of Moletest application, the combined measured attributes of a suspect legion compared to the outcome of a biopsy performed on the legion | The image and analysis by the application are performed within 10 minutes of the patient giving consent to be part of this study. The biopsy that will be used for comarison with the image analysis will be available to the Investigators approximatly 6 weeks later | 6 weeks turnaround for each sample |
Postoperative Remote Monitoring of Vital Signs in Older Cardiac Surgery Patients

Study Overview
=================
Brief Summary
-----------------
A significant number of elderly patients experience a complication after cardiac surgery. This study aims to determine if postoperative remote monitoring of vital signs can be used to identify medicatie risk factors for vital sign deterioration in older cardiac surgery patients. Single center pilot study. 100 older patients undergoing cardiac surgery. Continuous remote monitoring of vital signs after ICU discharge Main study endpoint is vital sign deterioration.

Detailed Description
-----------------
Cardiac surgery in elderly patients aims to improve functional capacity and overall survival but may also precipitate major morbidity and mortality. Despite major improvements in the safety of anesthesia and surgery a significant number of elderly patients experience a complication after cardiac surgery. To determine if postoperative remote monitoring of vital signs can be used to identify medication risk factors for vital sign deterioration in older cardiac surgery patients.. Single center pilot study. 100 older patients undergoing cardiac surgery. Continuous remote monitoring of vital signs starts after ICU discharge PR, RR and SpO2 will be continuously monitored in all patients. Patients and healthcare personnel are blinded for monitoring results. Main study endpoint is vital sign deterioration. The study population includes 100 patients ≥70 years undergoing elective cardiac surgery.

Official Title
-----------------
Postoperative Remote Monitoring of Vital Signs in Older Cardiac Surgery Patients

Conditions
-----------------
Hypoxemia, Respiratory Failure, Arrythmia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥70 years undergoing elective cardiac surgery. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypoxemia | Duration of sPO2 <80%, <85%, <90% and <95% in minutes per hour | Three consecutive days after ICU discharge | 
| Respiratory deterioration | Duration of respiratory rate <10 min-1, >20 min-1, >25 min-1, >30 min-1 in minutes per hour | Three consecutive days after ICU discharge | 
| Arrythmia | Duration of pulse rate <50 min-1, >100 min-1, >110 min-1, >120 min-1 in minutes per hour | Three consecutive days after ICU discharge |
Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome

Study Overview
=================
Brief Summary
-----------------
RATIONALE: The identification of gene mutations in individuals who have or are at risk for von Hippel-Lindau syndrome may allow doctors to better determine the genetic processes involved in the development of cancer. PURPOSE: This genetic study is finding gene mutations in participants with von Hippel-Lindau syndrome or who are at risk for developing von Hippel-Lindau syndrome.

Detailed Description
-----------------
OBJECTIVES: Obtain laboratory identification and confirmation of research results for gene mutations in participants previously enrolled in NCI-99-C-0053 who have von Hippel-Lindau (VHL) syndrome or who are at risk for VHL syndrome. Determine genotype status in these participants. OUTLINE: Participants submit a blood or buccal sample for genetic mutation analysis. Participants may receive genetic counseling and/or the results of genetic testing, if desired. PROJECTED ACCRUAL: A maximum of 260 participants will be accrued for this study.

Official Title
-----------------
Genetic Mutation Analysis In A VHL Population

Conditions
-----------------
Kidney Cancer, Von Hippel-lindau Syndrome

Intervention / Treatment
-----------------
* Genetic: mutation analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Prior enrollment in the von Hippel-Lindau (VHL) Syndrome Epidemiology Study NCI-99-C-0053 Meets 1 of the following criteria: Diagnosis of VHL syndrome At risk of VHL syndrome Family member of patient with VHL syndrome VHL syndrome genotype is not known PATIENT CHARACTERISTICS: Age Adult Performance status Not specified Life expectancy Not specified Hematopoietic Not specified Hepatic Not specified Renal Not specified PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: mutation analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
renal cell carcinoma, von Hippel-Lindau syndrome